Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Operating Expenses (2016 - 2024)

Historic Other Operating Expenses for Zevra Therapeutics (ZVRA) over the last 9 years, with Q2 2025 value amounting to $148.3 million.

  • Zevra Therapeutics' Other Operating Expenses changed N/A to $148.3 million in Q2 2025 from the same period last year, while for Sep 2025 it was $148.3 million, marking a year-over-year increase of 43134.89%. This contributed to the annual value of -$78.9 million for FY2023, which is 220.33% up from last year.
  • According to the latest figures from Q2 2025, Zevra Therapeutics' Other Operating Expenses is $148.3 million.
  • Zevra Therapeutics' Other Operating Expenses' 5-year high stood at $148.3 million during Q2 2025, with a 5-year trough of -$25.9 million in Q3 2023.
  • In the last 5 years, Zevra Therapeutics' Other Operating Expenses had a median value of $91000.0 in 2022 and averaged $8.9 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 305000.0% in 2021, then crashed by 2856153.85% in 2023.
  • Over the past 5 years, Zevra Therapeutics' Other Operating Expenses (Quarter) stood at $59000.0 in 2021, then surged by 55.93% to $92000.0 in 2022, then crashed by 26308.7% to -$24.1 million in 2023, then increased by 14.35% to -$20.7 million in 2024, then surged by 818.21% to $148.3 million in 2025.
  • Its last three reported values are $148.3 million in Q2 2025, -$20.7 million for Q1 2024, and -$24.1 million during Q4 2023.